Effect of fibulin-5 on adhesion, migration and invasion of hepatocellular carcinoma cells via an integrin-dependent mechanism

Table 2 Disease-specific survival by Cox regression analysis between the subgroups of various clincopathological parameters

Parameter		No.	No. of events	HR (95%CI)1	P value2
Age (yr)	< 50	54	18	0.373 (0.169-0.823)	0.158
	≥ 50	86	24
Gender	Male	113	30	0.864 (0.324-2.306)	0.771
	Female	27	12
Tumor size (cm)	< 5	82	23	1.874 (0.902-3.895)	0.093
	≥ 5	58	19
No. of tumor nodules	1	122	32	3.634 (1.481-8.916)	0.0053
	≥ 2	18	10
Recurrent cancer	Absent	87	15	0.587 (0.231-1.491)	0.263
	Present	53	28
Cirrhosis	Absent	50	14	0.924 (0.426-2.004)	0.841
	Present	90	29
Serum AFP level	Negative	79	21	0.615 (0.280-1.352)	0.227
	Positive	61	21
HBV	HBsAg (-)	32	11	1.487 (0.670-3.302)	0.329
	HBsAg (+)	108	31
TNM tumor stage	I + II	102	11	7.478 (2.571-21.753)	0.0013
	III + IV	38	31
BCLC tumor stage	0 + A	93	8	5.257 (1.707-16.186)	0.0043
	B + C + D	47	34
FBLN-5 Expression	High	95	13	4.276 (2.033-8.995)	0.0013
	Low	45	29

¹The 95% Wald Confidence Limits;

²Associations determined by Cox regression analyses;

³Statistically significant. AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; TNM: Tumor-node-metastasis; BCLC: Barcelona clinic liver cancer; FBLN-5: Fibulin-5; HBsAg: Hepatitis B surface antigen.